Biocytogen Elevates Preclinical Research Services and Global Engagement with Strategic Platform Upgrade and Website Relaunch
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKEX: 02315), a pioneering force in the biotechnology sector known for its cutting-edge antibody discovery and preclinical services, has taken a bold step forward in expanding its capabilities and global presence. The company announced a comprehensive upgrade to its preclinical business division—centered around an expanded portfolio of genetically engineered animal models and advanced service offerings. In parallel, it launched a newly designed global website tailored to support its growing international client base across biopharmaceutical and academic sectors.
With a mission to drive the development of novel antibody-based drugs through proprietary gene-editing and discovery technologies, Biocytogen’s latest strategic move underscores its commitment to supporting drug developers worldwide from the earliest stages of research through to IND-enabling studies. The platform upgrade includes a wider array of highly specialized mouse models—including target-humanized, immune-humanized, immunodeficient, and transgenic strains—as well as an end-to-end preclinical services suite encompassing in vivo efficacy evaluation, PK/PD analysis, biomarker studies, and non-GLP toxicology assessments. Coupled with this operational expansion is the launch of a multilingual, user-centric website that aims to better serve clients, partners, and collaborators across Asia, North America, and Europe.
A Deepened Focus on Preclinical Innovation
Preclinical research forms the foundation of every therapeutic breakthrough, and Biocytogen’s newly upgraded platform is designed to meet the diverse and evolving needs of this critical stage. With increasing demand for predictive and translational animal models, the company has expanded its core offering of genetically engineered mouse models, now exceeding 1,100 unique target-humanized strains.
These animal models are a product of Biocytogen’s proprietary in situ gene replacement technology, which replaces specific murine genes with their corresponding human counterparts while retaining natural gene regulation. The result is a physiologically relevant in vivo system capable of replicating human disease mechanisms more accurately than conventional transgenic or knockout models. By leveraging these models, researchers gain deeper insights into target biology, treatment mechanisms, and safety profiles—accelerating the drug development timeline from early research to clinical entry.
Since launching its BioMice® sub-brand in 2021, Biocytogen has positioned itself as a global leader in model generation. Its humanized mice now span therapeutic areas including oncology, autoimmune and inflammatory diseases, metabolic disorders, and neurological conditions. The collection includes high-value disease models such as humanized CD3 for testing T-cell engagers (TCEs), HER2 for tumor-associated antibody studies, TL1A for inflammatory bowel disease (IBD), TSLP for atopic dermatitis (AD), GLP1R for obesity and metabolic studies, and TFR1 for blood-brain barrier (BBB) delivery research.
These models are now used extensively by pharmaceutical companies and research institutions for drug screening, target validation, mechanism-of-action studies, and safety evaluation. Importantly, safety data generated using BioMice models have supported over 20 Investigational New Drug (IND) applications, including 15 approved by China’s National Medical Products Administration (NMPA) and five by the U.S. Food and Drug Administration (FDA)—with four of the latter being dual-country submissions.
A Multidimensional Preclinical Toolset for Global Clients
The company’s capabilities extend far beyond humanized mouse models. Its extensive model library also includes immune-humanized strains—such as huPBMC-B-NDG, huHSC-B-NDG, and advanced derivatives expressing human interleukin-15 or engineered with MHC class I/II deletions—as well as transgenic mice and immunodeficient models. These specialized systems support the preclinical evaluation of a broad spectrum of therapies, including T-cell and NK-cell therapies, immune checkpoint inhibitors, bispecific antibodies, and cytokine-based immunostimulants.
Biocytogen’s global impact is driven by the scale and quality of its operations. The company currently manages three state-of-the-art animal research and production facilities: two in China (Haimen, Jiangsu and Daxing, Beijing) and one in Boston, USA. All three are accredited by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC), ensuring adherence to the highest standards of animal welfare and experimental reproducibility.
Together, these facilities occupy a total area of 55,000 square meters and can produce over 800,000 lab animals per year. This capacity is supported by rigorous microbial quality control systems, standardized operating protocols, and a robust logistics framework that enables rapid and reliable delivery of research models. Biocytogen has now supplied mouse models to clients in more than 20 countries and regions, creating a global network of preclinical partners ranging from biotech startups to multinational pharmaceutical companies and academic institutions.
One-Stop Preclinical Solutions to Accelerate IND Filings
At the core of Biocytogen’s upgraded platform is an integrated suite of preclinical services, developed to provide a seamless transition from in vitro validation to in vivo efficacy and safety profiling. These services are non-GLP by design, allowing for flexibility and rapid turnaround times to support early-stage decision-making and regulatory submission planning.
The offering includes:
- In Vivo Efficacy Studies: Conducted in syngeneic, CDX (cell-derived xenograft), and PDX (patient-derived xenograft) tumor models across hematologic and solid malignancies.
- Pharmacokinetics/Pharmacodynamics (PK/PD): Supporting dose optimization, exposure-response relationships, and half-life determination.
- Biomarker Analysis: Enabling validation of therapeutic mechanisms, target engagement, and immune modulation using flow cytometry, IHC, ELISA, qPCR, and other modalities.
- Non-GLP Toxicology: Preliminary safety evaluations that inform the design of formal IND-enabling studies.
The breadth of Biocytogen’s preclinical services spans more than 20 therapeutic areas, including cancers (e.g., lung, breast, liver, pancreatic), autoimmune diseases (e.g., rheumatoid arthritis, psoriasis), metabolic conditions (e.g., diabetes, obesity), and central nervous system disorders (e.g., Alzheimer’s, Parkinson’s). The company has completed over 5,300 preclinical projects for nearly 900 clients worldwide, underscoring the trust it has earned as a dependable partner in translational research.
Antibody Discovery Powered by Proprietary RenMice® Platforms
Biocytogen’s contributions to drug development are not limited to animal modeling and preclinical services. The company has also emerged as a front-runner in antibody drug discovery, thanks to its internally developed RenMice® platforms. These platforms are purpose-built to generate fully human antibody repertoires with superior diversity, affinity, and developability.
The core RenMice® platforms include:
- RenMab™: Produces fully human antibodies through gene knock-in replacement of mouse immunoglobulin loci.
- RenLite®: A common light chain mouse model ideal for bispecific antibody discovery.
- RenNano®: Enables generation of fully human single-domain (VHH) antibodies.
- RenTCR™ and RenTCR-mimic™: Create T-cell receptor and TCR-mimic antibodies for intracellular antigen targeting.
Together, these technologies have enabled the generation of a library exceeding one million fully human antibody sequences covering over 1,000 distinct therapeutic targets. These antibodies have diverse functionalities, including receptor blockade, agonism, ADCC/CDC activation, bispecific engagement, and tumor penetration.
As of December 31, 2024, Biocytogen has inked approximately 200 collaboration agreements related to its RenMice® platforms. This includes more than 50 target-based co-development deals with major multinational pharmaceutical companies. Several clinical-stage candidates derived from RenMice have been successfully licensed to global partners, reinforcing Biocytogen’s reputation as a trusted source of next-generation antibody therapeutics.
Launch of a Revamped Global Website to Enhance Client Experience
In a move to reflect its expanded service capabilities and better support its growing international clientele, Biocytogen also unveiled its newly redesigned corporate website: https://biocytogen.com. The modernized digital platform is more than a cosmetic update—it represents a strategic investment in client communication, partner engagement, and global branding.
Key features of the new website include:
- Streamlined Architecture: Clear navigation paths organized around the company’s two business arms: BioMice® (preclinical models and services) and RenBiologics™ (antibody discovery and licensing).
- Expanded Content: Detailed information on over 1,100 humanized mouse models, antibody assets, preclinical service offerings, disease areas, and partner programs.
- Enhanced Search Capabilities: Improved filtering, keyword search, and asset browsing features to facilitate faster access to technical data.
- Multilingual Accessibility: The site is available in English, Chinese, Japanese, and Korean, ensuring usability for clients and partners across key global regions.
This digital transformation complements Biocytogen’s broader internationalization strategy, which seeks to build stronger ties with clients, CRO/CDMO partners, academic institutions, and biopharmaceutical collaborators across North America, Europe, and Asia-Pacific. The new website functions as both an informational hub and a client engagement tool—helping users stay informed, initiate collaborations, and access scientific resources more efficiently.
As Biocytogen embarks on this next chapter of growth, the company is focused on deepening its role as a platform enabler for the global biotech ecosystem. Through its expanded preclinical services, high-quality animal models, and best-in-class antibody discovery platforms, Biocytogen is accelerating the pace of therapeutic innovation—helping partners translate molecular insights into life-changing medicines with greater speed and precision.
From model development to clinical candidate selection, the company’s end-to-end capabilities provide an integrated solution for biopharmaceutical companies at every stage of drug development. With a strong foothold in Asia and expanding reach in the U.S. and Europe, Biocytogen is uniquely positioned to bridge discovery science with translational research—paving the way for the next generation of immunotherapies, biologics, and precision medicines.
The upgrade to its preclinical platform and launch of a redesigned website are more than operational milestones—they reflect Biocytogen’s strategic vision of building a global infrastructure for accelerated and collaborative drug development. As the biotech industry continues to evolve, Biocytogen’s scientific excellence, technology leadership, and global connectivity will remain at the forefront of reshaping the future of preclinical research and antibody innovation.
